WO2001070941A3 - An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis - Google Patents

An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis Download PDF

Info

Publication number
WO2001070941A3
WO2001070941A3 PCT/EP2001/003272 EP0103272W WO0170941A3 WO 2001070941 A3 WO2001070941 A3 WO 2001070941A3 EP 0103272 W EP0103272 W EP 0103272W WO 0170941 A3 WO0170941 A3 WO 0170941A3
Authority
WO
WIPO (PCT)
Prior art keywords
found
multiple sclerosis
gag
retrovirus
endogenous retrovirus
Prior art date
Application number
PCT/EP2001/003272
Other languages
French (fr)
Other versions
WO2001070941A2 (en
WO2001070941A9 (en
Inventor
Tove Christensen
Larsen Anne Moller
Sorensen Pernille Dissing
Poul Andersson
Original Assignee
Ms Res As
Tove Christensen
Larsen Anne Moller
Sorensen Pernille Dissing
Poul Andersson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ms Res As, Tove Christensen, Larsen Anne Moller, Sorensen Pernille Dissing, Poul Andersson filed Critical Ms Res As
Priority to EP01931543A priority Critical patent/EP1265989A2/en
Priority to AU58292/01A priority patent/AU5829201A/en
Priority to IL15186801A priority patent/IL151868A0/en
Priority to CA002403815A priority patent/CA2403815A1/en
Priority to JP2001569324A priority patent/JP2004502407A/en
Publication of WO2001070941A2 publication Critical patent/WO2001070941A2/en
Publication of WO2001070941A3 publication Critical patent/WO2001070941A3/en
Publication of WO2001070941A9 publication Critical patent/WO2001070941A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Retroviral sequences were characterised by RT-PCR with gag and env primers on RNA from RT-positive retroviral particles produced by multiple sclerosis (MS) derived B-lymphoblastoid cell lines. Sequence variants with high homology to the potentially functional subgroup RGH of the human endogenous retrovirus RTVL-H/HERV-H family were found. The same sequences were also specifically found in the particulate fraction of a series of MS patient plasma samples and were absent in controls. South-Western blots demonstrated the presence of a nucleic acid binding protein, corresponding in size and function to the nucleocapsid protein, Gag NC, of other retroviruses. Indications for transmission of the retrovirus to mononuclear blood cells from healthy human individuals and non-human animals were found. Cell cultures derived from peripheral blood from MS patients contained 5-15 % CD3+ T-cells and a specific splice variant of the env sequence comprising a region of the pol region was identified in such cultures.
PCT/EP2001/003272 2000-03-21 2001-03-21 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis WO2001070941A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01931543A EP1265989A2 (en) 2000-03-21 2001-03-21 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
AU58292/01A AU5829201A (en) 2000-03-21 2001-03-21 An infective endogenous retrovirus and its association with demyelinating diseases and other diseases
IL15186801A IL151868A0 (en) 2000-03-21 2001-03-21 An infective endogenous retrovirus and its association with demyelinating diseases and other diseases
CA002403815A CA2403815A1 (en) 2000-03-21 2001-03-21 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
JP2001569324A JP2004502407A (en) 2000-03-21 2001-03-21 Infectious endogenous retrovirus and its relationship to demyelinating and other diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000466 2000-03-21
DK200000466 2000-03-21
DK200000617 2000-04-12
DKPA200000617 2000-04-12

Publications (3)

Publication Number Publication Date
WO2001070941A2 WO2001070941A2 (en) 2001-09-27
WO2001070941A3 true WO2001070941A3 (en) 2002-08-08
WO2001070941A9 WO2001070941A9 (en) 2003-05-22

Family

ID=26068797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003272 WO2001070941A2 (en) 2000-03-21 2001-03-21 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis

Country Status (6)

Country Link
EP (1) EP1265989A2 (en)
JP (1) JP2004502407A (en)
AU (1) AU5829201A (en)
CA (1) CA2403815A1 (en)
IL (1) IL151868A0 (en)
WO (1) WO2001070941A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411262B (en) * 2001-09-27 2003-11-25 Wolff Klaus Dr HUMAN ENDOGENIC RETROVIRUS
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
JP5504163B2 (en) * 2008-09-18 2014-05-28 学校法人慶應義塾 Cancer diagnosis and treatment methods
UA119032C2 (en) * 2012-10-02 2019-04-25 Женеро Са Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650318A (en) * 1992-04-03 1997-07-22 Bio Merieux Process and culture medium for the production of cells infected by a multiple sclerosis-associated virus
WO1999053103A1 (en) * 1998-04-08 1999-10-21 Ms Research A/S Diagnosis of multiple sclerosis and other demyelinating diseases
US6001987A (en) * 1995-08-03 1999-12-14 Bio Merieux Isolated nucleotide sequences associated with Multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650318A (en) * 1992-04-03 1997-07-22 Bio Merieux Process and culture medium for the production of cells infected by a multiple sclerosis-associated virus
US6001987A (en) * 1995-08-03 1999-12-14 Bio Merieux Isolated nucleotide sequences associated with Multiple sclerosis
WO1999053103A1 (en) * 1998-04-08 1999-10-21 Ms Research A/S Diagnosis of multiple sclerosis and other demyelinating diseases

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
BLOND J-L ET AL: "Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family.", JOURNAL OF VIROLOGY, vol. 73, no. 2, February 1999 (1999-02-01), pages 1175 1175 - 1185, XP002902124 *
CHRISTENSEN T ET AL: "Characterization of retroviruses from patients with multiple sclerosis.", ACTA NEUROL SCAND 1997 SUPPLEMENT 169, Denmark, pages 49 - 58, XP002902110, ISSN: 0065-1427, ISBN: 87-16-15654-4 *
CHRISTENSEN T ET AL: "Expression of sequence variants of endogenous retrovirus RGH in particle form in multiple sclerosis", THE LANCET, vol. 352, 26 September 1998 (1998-09-26), pages 1033, XP002902107 *
CHRISTENSEN T ET AL: "Reverse transcriptase activity and particle production in B lymphoblastoid cell lines established from lymphocytes of patients with multiple sclerosis", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 15, no. 3, 1999, pages 285 - 291, XP002902108 *
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retovirus", XP002902111, retrieved from EMBL accession no. HE53031 *
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902112, retrieved from EMBL accession no. HE35032 *
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902113, retrieved from EMBL accession no. HE35033 *
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902114, retrieved from EMBL accession no. HSU88896 *
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902115, retrieved from EMBL accession no. HSU88897 *
DATABASE EMBL [online] LINDESKOG M ET AL: "Human endogenous retrovirus", XP002902116, retrieved from EMBL accession no. HSU88898 *
DATABASE EMBL LINDESKOG M ET AL: "Human endogenous retrovirus clone", XP002902118 *
GARSON J A ET AL: "Detection of virion-associated MSRV-RNA in serum of patients with multiple sclerosis.", LANCET, vol. 351, 1 March 1998 (1998-03-01), pages 33, XP002902122 *
GOODCHILD N L ET AL: "Spliced HERV-H endogenous retroviral sequences in human genomic DNA: evidence for amplification via retrotransposition.", VIROLOGY, vol. 206, 1995, pages 164 - 173, XP002902121 *
KOMURIAN-PRADEL F ET AL: "Molecular cloning and characterization of MSRV-related sequences associated with retrovirus-like particles", VIROLOGY, vol. 260, 1999, pages 1 - 9, XP002902123 *
LINDESKOG M ET AL: "Coamplification and dispersion of adjacent human endogenous retroviral HERV-H and HERV-E elements; presence of spliced hybrid transcripts in normal leukocytes.", VIROLOGY, vol. 244, 1998, pages 219 - 229, XP002902119, Retrieved from the Internet <URL:EMBL> *
LINDESKOG M ET AL: "Isolation of a human endogenous retroviral HERV-H element with an open env reading frame.", VIROLOGY, vol. 258, 1999, pages 441 - 450, XP002902120 *
LINDESKOG M ET AL: "Spliced human endogenous retroviral HERV-H env transcripts in T-cell leukaemia cell lines and normal leukocytes: alternative splicing pattern of HERV-H transcripts", JOURNAL OF GENERAL VIROLOGY, vol. 78, 1997, pages 2575 - 2585, XP002902117, Retrieved from the Internet <URL:EMBL> *
MOLLER-LARSEN A ET AL: "Isolation of a retrovirus from mutiple sclerosis patients in self-generated iodixanol gredients", JOURNAL OF VIROLOGICAL METHODS, vol. 73, 1998, pages 151 - 161, XP002902109 *

Also Published As

Publication number Publication date
WO2001070941A2 (en) 2001-09-27
IL151868A0 (en) 2003-04-10
JP2004502407A (en) 2004-01-29
EP1265989A2 (en) 2002-12-18
CA2403815A1 (en) 2001-09-27
WO2001070941A9 (en) 2003-05-22
AU5829201A (en) 2001-10-03

Similar Documents

Publication Publication Date Title
Nakamura et al. Redox regulation of cellular activation
Kajaste-Rudnitski et al. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-κB-responsive long terminal repeat elements
Dröge et al. Functions of glutathione and glutathione disulfide in immunology and immunopathology
Berberian et al. Immunoglobulin VH3 gene products: natural ligands for HIV gp120
Nair et al. Immunoregulatory effects of morphine on human lymphocytes
DE69737736D1 (en) INDUCTION OF REV AND TAT-SPECIFIC CYTOTOXIC T CELLS FOR THE PREVENTION AND TREATMENT OF INFECTION BY HUMAN IMMUNODICITY VIRUS (HIV)
EP1714974A3 (en) HIV-1-and HIV-2-peptides for inhibition of membranes fusion-associated events, including HIV transmission
Mansharamani et al. Barrier-to-Autointegration Factor BAF Binds p55 Gagand Matrix and Is a Host Component of Human ImmunodeficiencyVirus Type 1Virions
Weigent et al. The HTLV-III envelope protein contains a hexapeptide homologous to a region of interleukin-2 that binds to the interleukin-2 receptor
Cianciolo et al. Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferation
Li et al. Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose
Oravecz et al. CD26 expression correlates with entry, replication and cytopathicity of monocytotropic HIV–1 strains in a T–cell line
Shugars et al. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type 1
ES2010727A6 (en) Monoclonal antibodies to HIV and related peptides
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
Suciu-Foca et al. Reactivity of HTLV-transformed human T-cell lines to MHC class II antigens
WO2001070941A3 (en) An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
Dervillez et al. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV‐1 fusion inhibitory peptide C46
Minato et al. Regulation of the growth and functions of cloned murine large granular lymphocyte lines by resident macrophages.
Dekaban et al. Nucleotide sequence analysis of an HTLV-I isolate from a Chilean patient with HAM/TSP
Xu et al. GM-CSF restores innate, but not adaptive, immune responses in glucocorticoid-immunosuppressed human blood in vitro
Raj et al. Primary plasma cell leukemia occuring in the young
AU2006238617B2 (en) HIV Vif mutants
Gabrilovich et al. Influence of HIV antigens on functional activity of neutrophilic granulocytes in
OH et al. Partial purification and identification of an immunosuppressive factor in AIDS sera

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2403815

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 151868

Country of ref document: IL

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 569324

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 58292/01

Country of ref document: AU

Ref document number: 521762

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001931543

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018097421

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001931543

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGE 3/5, DRAWINGS, REPLACED BY A NEW PAGE 3/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2001931543

Country of ref document: EP